PROGRESS IN RECOMBINANT HUMAN SERUM ALBUMIN FOR BIOPHARMACEUTICAL PROGRAMS

Recombinant human serum albumin (OsrHSA) has emerged as a big innovation in the sphere of biopharmaceuticals, presenting promising progress throughout many clinical and industrial programs. With its structural similarity to Obviously derived human serum albumin, OsrHSA gives a safer, much more trustworthy option for therapeutic use, specifically in